Literature DB >> 18568339

Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Neal R Swerdlow1, Martin Weber, Ying Qu, Gregory A Light, David L Braff.   

Abstract

INTRODUCTION: Under specific conditions, a weak lead stimulus, or "prepulse", can inhibit the startling effects of a subsequent intense abrupt stimulus. This startle-inhibiting effect of the prepulse, termed "prepulse inhibition" (PPI), is widely used in translational models to understand the biology of brainbased inhibitory mechanisms and their deficiency in neuropsychiatric disorders. In 1981, four published reports with "prepulse inhibition" as an index term were listed on Medline; over the past 5 years, new published Medline reports with "prepulse inhibition" as an index term have appeared at a rate exceeding once every 2.7 days (n=678). Most of these reports focus on the use of PPI in translational models of impaired sensorimotor gating in schizophrenia. This rapid expansion and broad application of PPI as a tool for understanding schizophrenia has, at times, outpaced critical thinking and falsifiable hypotheses about the relative strengths vs. limitations of this measure.
OBJECTIVES: This review enumerates the realistic expectations for PPI in translational models for schizophrenia research, and provides cautionary notes for the future applications of this important research tool.
CONCLUSION: In humans, PPI is not "diagnostic"; levels of PPI do not predict clinical course, specific symptoms, or individual medication responses. In preclinical studies, PPI is valuable for evaluating models or model organisms relevant to schizophrenia, "mapping" neural substrates of deficient PPI in schizophrenia, and advancing the discovery and development of novel therapeutics. Across species, PPI is a reliable, robust quantitative phenotype that is useful for probing the neurobiology and genetics of gating deficits in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568339      PMCID: PMC2771731          DOI: 10.1007/s00213-008-1072-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  456 in total

1.  Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.

Authors:  J Sallinen; I Höglund; M Engström; J Lehtimäki; R Virtanen; J Sirviö; S Wurster; J-M Savola; A Haapalinna
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

2.  Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

Authors:  Lin Zhang; Yukihiko Shirayama; Masaomi Iyo; Kenji Hashimoto
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

3.  Selective nucleus accumbens core lesions enhance dizocilpine-induced but not apomorphine-induced disruption of prepulse inhibition in rats.

Authors:  Helen H J Pothuizen; Ken R Neumann; Joram Feldon; Benjamin K Yee
Journal:  Behav Pharmacol       Date:  2006-03       Impact factor: 2.293

4.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Authors:  Kirsten Krebs-Thomson; Erbert M Ruiz; Virginia Masten; Mahalah Buell; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

5.  Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder.

Authors:  Klaus Hoenig; Andrea Hochrein; Boris B Quednow; Wolfgang Maier; Michael Wagner
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

6.  An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition.

Authors:  Jacob C Ong; Suzanne A Brody; Charles H Large; Mark A Geyer
Journal:  J Pharmacol Exp Ther       Date:  2005-08-25       Impact factor: 4.030

7.  Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffrey A Lieberman; Beverly H Koller
Journal:  Pharmacol Biochem Behav       Date:  2006-11-13       Impact factor: 3.533

8.  Temporal course of emotional startle modulation in schizophrenia patients.

Authors:  Martin Volz; Alfons O Hamm; Peter Kirsch; Eibe-Rudolf Rey
Journal:  Int J Psychophysiol       Date:  2003-08       Impact factor: 2.997

9.  Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha.

Authors:  Thomas J Gould; Scott P Bizily; Jan Tokarczyk; Michele P Kelly; Steven J Siegel; Stephen J Kanes; Ted Abel
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

10.  Sensitivity of the five-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley rats.

Authors:  Tracie A Paine; Hilarie C Tomasiewicz; Kehong Zhang; William A Carlezon
Journal:  Biol Psychiatry       Date:  2007-03-07       Impact factor: 13.382

View more
  219 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  The learned safety paradigm as a mouse model for neuropsychiatric research.

Authors:  Daniela D Pollak; Francisco J Monje; Gert Lubec
Journal:  Nat Protoc       Date:  2010-04-29       Impact factor: 13.491

3.  Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder.

Authors:  Rebecca L Ashare; Larry W Hawk; Keri Shiels; Jessica D Rhodes; William E Pelham; James G Waxmonsky
Journal:  Psychophysiology       Date:  2010-03-10       Impact factor: 4.016

4.  The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.

Authors:  Martin Weber; Wei-Li Chang; Michelle R Breier; Alex Yang; Mark J Millan; Neal R Swerdlow
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-25       Impact factor: 4.600

Review 5.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

6.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

Review 7.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

8.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

9.  Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.

Authors:  Marjelo A Mines; Eleonore Beurel; Richard S Jope
Journal:  Eur J Pharmacol       Date:  2012-10-23       Impact factor: 4.432

10.  Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.

Authors:  Francesca Managò; Maddalena Mereu; Surjeet Mastwal; Rosa Mastrogiacomo; Diego Scheggia; Marco Emanuele; Maria A De Luca; Daniel R Weinberger; Kuan Hong Wang; Francesco Papaleo
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.